Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study
Authors' conclusion
Five years of T2T-ULT resulted in most patients achieving sUA target, reduction of crystal depositions, and dissolution of double contour and tophi in most patients.
Study context
- Population
- Patients with a recent gout flare initiating treat-to-target urate-lowering therapy (T2T-ULT) (outpatient clinic year 1, general practitioner years 2–5)163 examined at 5 years
- Participants
- 209 patients
- Outcome
- Maintenance of low sUA during T2T-ULT and change in US-detected crystal depositions, complete dissolution of depositions, and reduction of flares
- Follow-up
- 5 years
Methodological detailstreat-to-target, 5-year follow-up
- Treat-to-target
- 5-year follow-up
Main finding
As reported in the abstract
sUA, US crystal depositions and flares at 5 years
- Serum uric acid (sUA) reduced from baseline to 5 years (μmol/L), P < .001
- 500 to 337
- sUA <360 μmol/L
- 71.2%
- Full dissolution of double contour
- 83.4%
- Full dissolution of tophi
- 63.2%
- Flares the previous year (all with higher sUA and depositions, P = .035-.006)
- 16%
Observational data: associations, not effects.
Original publication
Ultrasound-detected crystal depositions and clinical flares dissolve during successful urate-lowering therapy: 5-year follow-up results from the treat-to-target NOR-Gout study. Ann Rheum Dis. Published 20 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →